GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » We Can Medicines Co Ltd (ROCO:6929) » Definitions » Debt-to-Equity

We Can Medicines Co (ROCO:6929) Debt-to-Equity : 1.12 (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is We Can Medicines Co Debt-to-Equity?

We Can Medicines Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was NT$242 Mil. We Can Medicines Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was NT$1,046 Mil. We Can Medicines Co's Total Stockholders Equity for the quarter that ended in Sep. 2024 was NT$1,147 Mil. We Can Medicines Co's debt to equity for the quarter that ended in Sep. 2024 was 1.12.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for We Can Medicines Co's Debt-to-Equity or its related term are showing as below:

ROCO:6929' s Debt-to-Equity Range Over the Past 10 Years
Min: 1.03   Med: 1.32   Max: 1.62
Current: 1.12

During the past 4 years, the highest Debt-to-Equity Ratio of We Can Medicines Co was 1.62. The lowest was 1.03. And the median was 1.32.

ROCO:6929's Debt-to-Equity is ranked worse than
82.44% of 1646 companies
in the Consumer Packaged Goods industry
Industry Median: 0.395 vs ROCO:6929: 1.12

We Can Medicines Co Debt-to-Equity Historical Data

The historical data trend for We Can Medicines Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

We Can Medicines Co Debt-to-Equity Chart

We Can Medicines Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
1.03 1.32 1.34 1.62

We Can Medicines Co Quarterly Data
Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.57 1.62 1.23 1.11 1.12

Competitive Comparison of We Can Medicines Co's Debt-to-Equity

For the Packaged Foods subindustry, We Can Medicines Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


We Can Medicines Co's Debt-to-Equity Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, We Can Medicines Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where We Can Medicines Co's Debt-to-Equity falls into.



We Can Medicines Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

We Can Medicines Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

We Can Medicines Co's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


We Can Medicines Co  (ROCO:6929) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


We Can Medicines Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of We Can Medicines Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


We Can Medicines Co Business Description

Traded in Other Exchanges
N/A
Address
Section 4, Taiwan Avenue, 20th Floor-1, No. 925, Xitun District, Taichung, TWN
We Can Medicines Co Ltd is a Taiwan-based company mainly engaged in the operation of chain cosmeceutical drugstores. The Company's main products include pharmaceuticals and health food, maternity and infant products, medical supplies, beauty cosmetics, and daily necessities.

We Can Medicines Co Headlines

No Headlines